Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

Today, ARCH Biopartners Inc., ("ARCH" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that ARCH is receiving advisory services and up to $4,000,000 in funding from the National ReseARCH Council of Canada Industrial ReseARCH Assistance Program ("NRC IRAP") to support the reseARCH and development of the LSALT peptide (Metablok) program. LSALT peptide is the Company's lead drug candidate for treating acute inflammation injury in the lungs, kidneys and liver.

The research and development funding from NRC IRAP will help support several sub-tasks needed to advance the LSALT peptide drug program. These include: dose escalation studies; costs incurred by Arch during the Canadian Treatments for COVID-19 Phase III human trial; manufacturing new drug product supply to support future non-COVID human trials; the non-COVID Phase II trials (such as a cardiac surgery associated acute kidney injury trial) to gather more human data to support future drug approval; and, additional non-clinical studies to discover potential biomarkers and to further understand the mechanism of action related to LSALT peptide.

Quote from Richard Muruve, CEO of Arch Biopartners:

" We appreciate this support from NRC IRAP as we continue to develop LSALT Peptide as a treatment for inflammation injury in the lungs, kidneys and liver. This project funding will enable Arch to complete several important drug development tasks in the next twelve months."

The term of the Project extends to March 31, 2024.

About Arch Biopartners

Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch Biopartners is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP-1) pathway, relevant for multiple medical indications.

For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com

The Company has 62,398,825 common shares outstanding.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of our future performance, liquidity and capital resources, as well as the ongoing clinical development of our drug candidates targeting the dipeptidase-1 (DPEP-1) pathway, including the outcome of our clinical trials relating to LSALT Peptide (Metablok), the successful commercialization and marketing of our drug candidates, whether we will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe and other countries, our ability to raise capital to fund our business plans, the efficacy of our drug candidates compared to the drug candidates developed by our competitors, our ability to retain and attract key management personnel, and the breadth of, and our ability to protect, our intellectual property portfolio. These statements are based on management's current expectations and beliefs, including certain factors and assumptions, as described in our most recent annual audited financial statements and related management discussion and analysis under the heading "Business Risks and Uncertainties". As a result of these risks and uncertainties, or other unknown risks and uncertainties, our actual results may differ materially from those contained in any forward-looking statements. The words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We undertake no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including our most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval ("SEDAR") website at www.sedar.com .

The science and medical contents of this release have been approved by the Company's Chief Science Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release



For more information, please contact: Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 info@archbiopartners.com

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ARCH
The Conversation (0)
First Helium Reviewing Potential Follow Up Targets to Leduc Anomaly Drill

First Helium Reviewing Potential Follow Up Targets to Leduc Anomaly Drill

First Helium Inc. ("First Helium" or the "Company") (TSXV: HELI) (OTCQB: FHELF) (FRA: 2MC) today announced that it is reviewing its extensive drilling inventory for follow up operations to its planned Leduc anomaly drill ("7-15") targeting light oil. This program may include drilling its proven undeveloped 1, 3 location ("7-30"), a follow up well on the Leduc anomaly, or another one of 12 primary Leduc prospects identified on its proprietary 3D seismic at Worsley. Other operations include completion and testing of the existing 5-27 horizontal well, along with the re-entry and completion of an existing vertical well bore at east Worsley, both targeting helium-enriched natural gas in the Blue Ridge formation to establish a regional, repeatable play.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
First Helium Closes Upsized $3.64 Million Placement

First Helium Closes Upsized $3.64 Million Placement

Not for distribution to United States newswire services or for dissemination in the United States.

First Helium Inc. ("First Helium" or the "Company") (TSXV: HELI) (OTCQB: FHELF) (FRA: 2MC) today announced the closing of its upsized non-brokered private placement financing which was previously announced in the Company's press release dated October 16, 2024 and October 21, 2024. First Helium issued 60,666,671 units ("Units") at a price of $0.06 per Unit for gross proceeds of $3,640,000.26 (the "Offering) . All monetary figures in Canadian Dollars.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
GTI Energy

Lo Herma ISR Uranium Project, Resource Drilling Funded

Following the recently completed placement to sophisticated and institutional shareholders, GTI Energy Ltd (GTI or Company) is pleased to provide an update on the upcoming resource expansion drilling program at the Lo Herma ISR uranium project in Wyoming’s Powder River Basin (PRB). In advance of further news related to progress of the planned drill program at Lo Herma, the following provides a summary of the resource expansion potential and objectives of the 2024 Phase II drilling.

Keep reading...Show less
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Phase 12 pivotal study met the primary safety and efficacy endpoints –

51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012; complete responses have been durable beyond 12 months with median duration of follow up of 20 months as of data cutoff –

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
RUA GOLD Provides an Update on the Reefton Drilling Program and the next phase of drill targets

RUA GOLD Provides an Update on the Reefton Drilling Program and the next phase of drill targets

RUA GOLD Corporation (CSE: RUA) (OTC: NZAUF) (WKN: A4010V) ("RUA GOLD" or the "Company") is pleased to provide an exploration update for the Reefton Project on the South Island of New Zealand .

  • Preliminary results confirm the Pactolus system extends south for 550 meters along strike and is well mineralized on surface.
  • The Company is analyzing the results to better understand the plunge and tenor of the ore shoots at this early stage of exploration.
  • The Company has developed multiple new high-grade targets at past producing mines in the Murray Creek area for drill testing in Q2/2024.

Pactolus

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Rox Resources

High grade Assay Results Continue at Youanmi

West Australian gold exploration and development company, Rox Resources Limited (“Rox” or “the Company”) (ASX: RXL), has received the final batch of assays from its 11,000m DD and RC program at the Youanmi Gold Project in WA.

Keep reading...Show less
Alice Queen

Drilling Commenced at Viani in Fiji

Alice Queen Limited (ASX:AQX) (“Alice Queen” or the “Company”) is pleased to announce that drilling has commenced at its 100% owned Viani Project in Vanua Levu, Fiji (see Image 1). The initial planned three-hole diamond drilling program will test for high-grade epithermal gold-style mineralisation intersected at the Viani Project by historic drilling.

Keep reading...Show less
Firefly Metals logo

FireFly Drills its Best Hole Yet with Assay of 86.3m at 3.7% CuEq

Latest drilling returns very thick intersections with exceptional grades, outlining a rich area of mineralistion which will form part of the next Resource update

FireFly Metals Ltd (ASX: FFM) (“Company” or “Firefly”) is pleased to announce its best assays yet at the Green Bay copper-gold project.

Keep reading...Show less
Corazon Mining

Strategic Expansion of MacBride Base & Precious Metal Project in Canada

Acquired ground more than doubles Corazon’s prospective landholding / Aerial geophyical survey extended to test new tenure / Work underway defining priority targets for early 2025 drill program

Corazon Mining Limited (ASX: CZN) (Corazon or Company) is pleased to announce the strategic expansion of its MacBride Base and Precious Metals Project (MacBride or Project) in the Lynn Lake district, of Manitoba, Canada.

Keep reading...Show less

Latest Press Releases

Related News

×